A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti–IL-6R treatment
Open Access
- 22 September 2016
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 1 (15) , e88181
Abstract
Transgenic expression of key myelosupportive human cytokines in immune-deficient mice corrects for the lack of cross-species activities of stem cell factor (SCF), IL-3, and GM-CSF. When engrafted with human umbilical cord blood (UCB), these triple-transgenic mice produce BM and spleen grafts with much higher myeloid composition, relative to nontransgenic controls. Shortly after engraftment with UCB, these mice develop a severe, fatal macrophage activation syndrome (MAS) characterized by a progressive drop in rbc numbers, increased reticulocyte counts, decreased rbc half-life, progressive cytopenias, and evidence of chronic inflammation, including elevated human IL-6. The BM becomes strikingly hypocellular, and spleens are significantly enlarged with evidence of extramedullary hematopoiesis and activated macrophages engaged in hemophagocytosis. This manifestation of MAS does not respond to lymphocyte-suppressive therapies such as steroids, i.v. immunoglobulin, or antibody-mediated ablation of human B and T cells, demonstrating a lymphocyte-independent mechanism of action. In contrast, elimination of human myeloid cells using gemtuzumab ozogamicin (anti-CD33) completely reversed the disease. Additionally, the IL-6R antibody tocilizumab delayed progression and prolonged lifespan. This new model of MAS provides an opportunity for investigation of the mechanisms driving this disease and for the testing of directed therapies in a humanized mouse.Keywords
This publication has 64 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- Biologic therapy for autoimmune diseases: an updateBMC Medicine, 2013
- Membrane-bound human SCF/KL promotes in vivo human hematopoietic engraftment and myeloid differentiationBlood, 2012
- Protection from Inflammatory Organ Damage in a Murine Model of Hemophagocytic Lymphohistiocytosis Using Treatment with IL-18 Binding ProteinFrontiers in Immunology, 2012
- Not all hemophagocytes are created equallyCurrent Opinion in Rheumatology, 2012
- Novel Mouse Xenograft Models Reveal a Critical Role of CD4+ T Cells in the Proliferation of EBV-Infected T and NK CellsPLOS Pathogens, 2011
- Repeated TLR9 stimulation results in macrophage activation syndrome–like disease in miceJournal of Clinical Investigation, 2011
- Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor–, granulocyte-macrophage colony-stimulating factor–, and interleukin-3–expressing NOD-SCID IL2Rγnull humanized miceBlood, 2011
- Inflammasome activation in NADPH oxidase defective mononuclear phagocytes from patients with chronic granulomatous diseaseBlood, 2010
- Neutralization of IFNγ defeats haemophagocytosis in LCMV‐infected perforin‐ and Rab27a‐deficient miceEMBO Molecular Medicine, 2009